The potential and limitations of p38MAPK as a drug target for the treatment of hematological malignancies

Current Drug Targets

Volumn 11, Issue 7, 2010, Pages 823-833

  Gaundar, Shivashni S ^a   Bendall, Linda J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Apoptosis; Bone marrow stroma; Chemotherapy; Hematological malignancy; p38MAPK; Proliferation

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ARSENIC DERIVATIVE; ARSENIC SULFIDE; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BORTEZOMIB; CLADRIBINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GENISTEIN; GW 856553; HISTONE DEACETYLASE INHIBITOR; IMATINIB; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; NONSTEROID ANTIINFLAMMATORY AGENT; PAMAPIMOD; RESVERATROL; RITUXIMAB; RO 4402257; SB 681323; SCIO 469; SEMAPIMOD; SULINDAC; UNCLASSIFIED DRUG; VINBLASTINE; VX 702;

ACUTE CORONARY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL FUNCTION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXICITY; DEPRESSION; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE REARRANGEMENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROPATHIC PAIN; NONHUMAN; OSTEOCLASTOGENESIS; PLEIOTROPY; PROMYELOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CYTOKINES; DRUG DELIVERY SYSTEMS; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HUMANS; MODELS, BIOLOGICAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 77954726295     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791320854     Document Type: Article

References (164)

1. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000; 12: 1-13.
2. Verma A, Deb DK, Sassano A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem 2002; 277: 7726-35.
3. Jiang Y, Gram H, Zhao M, et al. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. J Biol Chem 1997; 272: 30122-8.
4. Adams RH, Porras A, Alonso G, et al. Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 2000; 6: 109-16.
5. Mudgett J, Ding J, Guh-Siesel L, et al. Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci USA 2000; 97: 10454-9.
6. Beardmore VA, Hinton HJ, Eftychi C, et al. Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol 2005; 25: 10454-64.
7. Sabio G, Arthur JS, Kuma Y, et al. p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J 2005; 24: 1134-45.
8. Lechner C, Zahalka MA, Giot JF, Moller NP, Ullrich A. ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. Proc Natl Acad Sci USA 1996; 93: 4355-9.
9. Wang XS, Diener K, Manthey CL, et al. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem 1997; 272: 23668-74.
10. Stein B, Yang MX, Young DB, et al. p38-2, a novel mitogen- activated protein kinase with distinct properties. J Biol Chem 1997; 272: 19509-17.
11. Jiang Y, Chen C, Li Z, et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 1996; 271: 17920-6.
12. Noh JS, Kang HJ, Kim EY, et al. Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH(2)-terminal protein kinase. J Neurochem 2000; 75: 2327-34.
13. Keesler GA, Bray J, Hunt J, et al. Purification and activation of recombinant p38 isoforms alpha, beta, gamma, and delta. Protein Expr Purif 1998; 14: 221-8.
14. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem 1998; 273: 1741-8.
15. Ge B, Gram H, Di Padova F, et al. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science 2002; 295: 1291-4.
16. Salvador JM, Mittelstadt PR, Guszczynski T, et al. Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol 2005; 6: 390-5.
17. Hildesheim J, Salvador JM, Hollander MC, Fornace AJ Jr. Casein kinase 2- and protein kinase A-regulated adenomatous polyposis coli and beta-catenin cellular localization is dependent on p38 MAPK. J Biol Chem 2005; 280: 17221-6.
18. Almholt DL, Loechel F, Nielsen SJ, et al. Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 redistribution screen. Assay Drug Dev Technol 2004; 2: 7- 20.
19. Fukunaga R, Hunter T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J 1997; 16: 1921-33.
20. Goebeler M, Gillitzer R, Kilian K, et al. Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood 2001; 97: 46-55.
21. Bulavin D, Higashimoto Y, Popoff I, et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 2001; 411: 102-7.
22. Perfettini J-L, Castedo M, Nardacci R, et al. Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. J Exp Med 2005; 201: 279-89.
23. Tanoue T, Yamamoto T, Maeda R, Nishida E. A Novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs. J Biol Chem 2001; 276: 26629-39.
24. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell 2000; 102: 221-31.
25. Nagata Y, Moriguchi T, Nishida E, Todokoro K. Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. Blood 1997; 90: 929-34.
26. Nagata Y, Takahashi N, Davis RJ, Todokoro K. Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin- induced erythroid differentiation. Blood 1998; 92: 1859-69.
27. Jacobs-Helber SM, Ryan JJ, Sawyer ST. JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells. Blood 2000; 96: 933-40.
28. Witt O, Sand K, Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 2000; 95: 2391-6.
29. Somervaille TC, Linch DC, Khwaja A. Different levels of p38 MAP kinase activity mediate distinct biological effects in primary human erythroid progenitors. Br J Haematol 2003; 120: 876-86.
30. Kuida K, Boucher DM. Functions of MAP kinases: insights from gene-targeting studies. J Biochem 2004; 135: 653-6.
31. Dalmas DA, Tierney LA, Zhang C, et al. Effects of p38 MAP kinase inhibitors on the differentiation and maturation of erythroid progenitors. Toxicol Pathol 2008; 36: 958-71.
32. Uddin S, Ah-Kang J, Ulaszek J, Mahmud D, Wickrema A. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci USA 2004; 101: 147-52.
33. Uddin S, Majchrzak B, Woodson J, et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem 1999; 274: 30127-31.
34. Katsoulidis E, Li Y, Yoon P, et al. Role of the p38 mitogen- activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res 2005; 65: 9029-37.
35. Verma A, Deb DK, Sassano A, et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol 2002; 168: 5984-8.
36. Foltz I, Lee J, Young P, Schrader J. Hemopoietic growth factors with the exception of interleukin-4 activate the p38 mitogen- activated protein kinase pathway. J Biol Chem 1997; 272: 3296- 301.
37. Rausch O, Marshall CJ. Cooperation of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways during granulocyte colony-stimulating factor-induced hemopoietic cell proliferation. J Biol Chem 1999; 274: 4096-105.
38. Ertesvag A, Aasheim H, Naderi S, Blomhoff H. Vitamin A potentiates CpG-mediated memory B cell proliferation and differentiation: Involvement of early activation of p38MAPK. Blood 2007; 109: 3865-72.
39. Wang S, Nath N, Minden A, Chellappan S. Regulation of Rb and E2F by signal transduction cascades: divergent effects of JNK1 and p38 kinases. EMBO J 1999; 18: 1559-70.
40. Nath N, Wang S, Betts V, Knudsen E, Chellappan S. Apoptotic and mitogenic stimuli inactivate Rb by differential utilization of p38 and cyclin-dependent kinases. Oncogene 2003; 22: 5986-94.
41. Hou ST, Xie X, Baggley A, Park DS, Chen G, Walker T. Activation of the Rb/E2F1 pathway by the nonproliferative p38 MAPK during Fas (APO1/CD95)-mediated neuronal apoptosis. J Biol Chem 2002; 277: 48764-70.
42. Pedraza-Alva G, Koulnis M, Charland C, et al. Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint. EMBO J 2006; 25: 763-73.
43. Wood CD, Thornton TM, Sabio G, Davis RA, Rincon M. Nuclear localization of p38 MAPK in response to DNA damage. Int J Biol Sci 2009; 5: 428-37.
44. Thornton TM, Pedraza-Alva G, Deng B, et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008; 320: 667-70.
45. Ringshausen I, Dechow T, Schneller F, et al. Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 2004; 18: 1964-70.
46. Elenitoba-Johnson K, Jenson S, Abbott R, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 2003; 100: 7259-64.
47. Yasui H, Hideshima T, Ikeda H, et al. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen- activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Br J Haematol 2007; 136: 414-23.
48. Kamiguti A, Harris R, Slupsky J, Baker P, Cawley J, Zuzel M. Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways. Oncogene 2003; 22: 2272-84.
49. Bendall LJ, Baraz R, Juarez J, Shen W, Bradstock KF. Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer Res 2005; 65: 3290-8.
50. Ogasawara T, Yasuyama M, Kawauchi K. Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders. Int J Hematol 2003; 77: 364-70.
51. Saulle E, Riccioni R, Coppola S, et al. Colocalization of the VEGF-R2 and the common IL-3/GM-CSF receptor beta chain to lipid rafts leads to enhanced p38 activation. Br J Haematol 2009; 145: 399-411.
52. Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa S. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis 2003; 31: 11-7.
53. Sanchez-Arevalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, et al. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J 2005; 387: 231-8.
54. Korus M, Mahon GM, Cheng L, Whitehead IP. p38 MAPK- mediated activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene 2002; 21: 4601-12.
55. Parmar S, Katsoulidis E, Verma A, et al. Role of the p38 mitogen- activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 2004; 279: 25345-52.
56. Ranganathan A, Adam A, Aguirre-Ghiso J. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 2006; 5: 1799-807.
57. Hirosawa M, Nakahara M, Otosaka R, Imoto A, Okazaki T, Takahashi S. The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells. Leuk Res 2009; 33: 693-9.
58. Srinivasa S, Doshi P. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia 2002; 16: 244-53.
59. Merkerova M, Bruchova H, Brdicka R. JNK2 and p38 MAPK over-expressions do not represent key events in chronic myeloid leukemia transformation. Neoplasma 2007; 54: 503-10.
60. Gaundar SS, Bradstock KF, Bendall LJ. p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells. Cell Cycle 2009; 8: 2975-83.
61. Okabe S, Tauchi T, Nakajima A, et al. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev 2007; 16: 503-14.
62. Kurosu T, Takahashi Y, Fukuda T, Koyama T, Miki T, Miura O. p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide. Apoptosis 2005; 10: 1111-20.
63. Miller A, Webb M, Copik A, et al. p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol 2005; 19: 1569-83.
64. Stadheim TA, Xiao H, Eastman A. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res 2001; 61: 1533-40.
65. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002; 99: 1314-9.
66. Lu J, Quearry B, Harada H. p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells. FEBS Lett 2006; 580: 3539-44.
67. Choi CH, Xu H, Bark H, et al. Balance of NF-kappaB and p38 MAPK is a determinant of radiosensitivity of the AML-2 and its doxorubicin-resistant cell lines. Leuk Res 2007; 31: 1267-76.
68. Giafis N, Katsoulidis E, Sassano A, et al. Role of the p38 mitogen- activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 2006; 66: 6763- 71.
69. Conrad DM, Robichaud MR, Mader JS, et al. 2-Chloro-2'- deoxyadenosine-induced apoptosis in T leukemia cells is mediated via a caspase-3-dependent mitochondrial feedback amplification loop. Int J Oncol 2008; 32: 1325-33.
70. Vaidya AA, Sharma MB, Kale VP. Suppression of p38-stress kinase sensitizes quiescent leukemic cells to anti-mitotic drugs by inducing proliferative responses in them. Cancer Biol Ther 2008; 7: 1232-40.
71. Junttila M, Li S, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008; 22: 954-65.
72. Roos W, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006; 12: 440-50.
73. Barancik M, Bohacova V, Kvackajova J, Hudecova S, Krizanova O, Breier A. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 2001; 14: 29-36.
74. Wen J, Cheng HY, Feng Y, et al. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 2008; 140: 169-80.
75. Hideshima T, Podar K, Chauhan D, et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004; 23: 8766-76.
76. Wen J, Feng Y, Huang W, et al. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 2010; 34: 85-92.
77. Navas T, Mohindru M, Estes M, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006; 108: 4170-7.
78. Guay J, Lambert H, Gingras-Breton G, Lavoie JN, Huot J, Landry J. Regulation of actin filament dynamics by p38 map kinase- mediated phosphorylation of heat shock protein 27. J Cell Sci 1997; 110: 357-68.
79. Mehlen P, Preville X, Chareyron P, Briolay J, Klemenz R, Arrigo AP. Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. J Immunol 1995; 154: 363-74.
80. Bruey JM, Ducasse C, Bonniaud P, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2000; 2: 645-52.
81. Reinhardt H, Yaffe M. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009; 21: 245-55.
82. Takenaka K, Moriguchi T, Nishida E. Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. Science 1998; 280: 599-602.
83. Raman M, Earnest S, Zhang K, Zhao Y, Cobb M. TAO kinases mediate activation of p38 in response to DNA damage. EMBO J 2007; 26: 2005-14.
84. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11: 175-89.
85. Mikhailov A, Shinohara M, Rieder C. Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol 2004; 166: 517-26.
86. Matsusaka T, Pines J. Chfr acts with the p38 stress kinases to block entry to mitosis in mammalian cells. J Cell Biol 2004; 166: 507-16.
87. Bulavin D, Saito S, Hollander M, et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18: 6845-54.
88. Shimada M, Nakanishi M. DNA damage checkpoints and cancer. J Mol Histol 2006; 37: 253-60.
89. Wang XW, Zhan Q, Coursen JD, et al. GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 1999; 96: 3706-11.
90. Yang Q, Manicone A, Coursen JD, et al. Identification of a functional domain in a GADD45-mediated G2/M checkpoint. J Biol Chem 2000; 275: 36892-8.
91. Kishi H, Nakagawa K, Matsumoto M, et al. Osmotic shock induces G1 arrest through p53 phosphorylation at Ser33 by activated p38MAPK without phosphorylation at Ser15 and Ser20. J Biol Chem 2001; 276: 39115-22.
92. Lemaire M, Froment C, Boutros R, et al. CDC25B phosphorylation by p38 and MK-2. Cell Cycle 2006; 5: 1649-53.
93. Goloudina A, Yamaguchi H, Chervyakova D, Appella E, Fornace AJ, Bulavin D. Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle 2003; 2: 473-8.
94. Khaled A, Bulavin D, Kittipatarin C, et al. Cytokine-driven cell cycling is mediated through Cdc25A. J Cell Biol 2005; 169: 755- 63.
95. Lavoie J, L'Allemain G, Brunet A, Müller R, Pouysségur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996; 271: 20608-16.
96. Yee A, Paulson E, McDevitt M, et al. The HBP1 transcriptional repressor and the p38 MAP kinase: unlikely partners in G1 regulation and tumor suppression. Gene 2004; 336: 1-13.
97. Casanovas O, Miro F, Estanyol J, Itarte E, Agell N, Bachs O. Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2- dependent manner. J Biol Chem 2000; 275: 35091-7.
98. Casanovas O, Jaumot M, Paules AB, Agell N, Bachs O. P38SAPK2 phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradation. Oncogene 2004; 23: 7537-44.
99. Bulavin D, Phillips C, Nannenga B, et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK- mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 2004; 36: 343-50.
100. Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006; 12: 446-51.
101. Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem 2002; 277: 29792-802.
102. Jirmanova L, Bulavin DV, Fornace AJ Jr. Inhibition of the ATR/Chk1 pathway induces a p38-dependent S-phase delay in mouse embryonic stem cells. Cell Cycle 2005; 4: 1428-34.
103. Manke I, Nguyen A, Lim D, Stewart M, Elia A, Yaffe M. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 2005; 17: 37-48.
104. Scicchitano M, McFarland D, Tierney L, et al. Role of p38 in regulation of hematopoiesis: effect of p38 inhibition on cytokine production and transcription factor activity in human bone marrow stromal cells. Blood Cells Mol Dis 2008; 40: 370-80.
105. Oster W, Cicco NA, Klein H, et al. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 1989; 84: 451-7.
106. Tobler A, Moser B, Dewald B, et al. Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood 1993; 82: 2517-25.
107. Skinnider B, Mak T. The role of cytokines in classical Hodgkin's lymphoma. Blood 2002; 99: 4283-97.
108. Chiu A, Xu W, He B, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007; 109: 729-39.
109. Mori N, Shirakawa F, Murakami S, Oda S, Eto S. Interleukin-1 alpha as an autocrine growth factor for acute lymphoblastic leukaemia cells. Br J Haematol 1994; 86: 386-8.
110. Freedman MH, Grunberger T, Correa P, Axelrad AA, Dube ID, Cohen A. Autocrine and paracrine growth control by granulocyte- monocyte colony-stimulating factor of acute lymphoblastic leukemia cells. Blood 1993; 81: 3068-75.
111. Kebelmann-Betzing C, Korner G, Badiali L, et al. Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor all. Cytokine 2001; 13: 39-50.
112. Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001; 97: 483-9.
113. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739-46.
114. Beyaert R, Cuenda A, Vanden Berghe W, et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 1996; 15: 1914-23.
115. Hashimoto S, Matsumoto K, Gon Y, et al. p38 MAP kinase regulates TNF alpha-, IL-1 alpha- and PAF-induced RANTES and GM-CSF production by human bronchial epithelial cells. Clin Exp Allergy 2000; 30: 48-55.
116. Griego SD, Weston CB, Adams JL, Tal-Singer R, Dillon SB. Role of p38 mitogen-activated protein kinase in rhinovirus-induced cytokine production by bronchial epithelial cells. J Immunol 2000; 165: 5211-20.
117. Navas TA, Nguyen AN, Hideshima T, et al. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006; 20: 1017-27.
118. Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003; 101: 703-5.
119. Nguyen A, Stebbins E, Henson M, et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res 2006; 312: 1909-23.
120. Juarez J, Bradstock K, Gottlieb D, Bendall L. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003; 17: 1294-300.
121. Manabe A, Coustan-Smith E, Behm F, Raimondi S, Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992; 79: 2370-7.
122. Scholzel C, Lowenberg B. Stimulation of proliferation and differentiation of acute myeloid leukemia cells on a bone marrow stroma in culture. Exp Hematol 1985; 13: 664-9.
123. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996; 92: 97-103.
124. Bendall LJ, Daniel A, Kortlepel K, Gottlieb DJ. Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol 1994; 22: 1252-60.
125. Manabe A, Murti KG, Coustan-Smith E, et al. Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood 1994; 83: 758-66.
126. Lundell BI, McCarthy JB, Kovach NL, Verfaillie CM. Activation- dependent alpha5beta1 integrin-mediated adhesion to fibronectin decreases proliferation of chronic myelogenous leukemia progenitors and K562 cells. Blood 1996; 87: 2450-8.
127. Wang M, Consoli U, Lane C, et al. Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. Cell Growth Differ 1998; 9: 105-12.
128. Yoshida H, Nishiura T, Karasuno T, et al. Effect of the interaction between fibronectin and VLA-4 on the proliferation of human B cells, especially a novel human B-cell line, OPM-3. Br J Haematol 1998; 103: 804-12.
129. Heuertz RM, Tricomi SM, Ezekiel UR, Webster RO. C-reactive protein inhibits chemotactic peptide-induced p38 mitogen-activated protein kinase activity and human neutrophil movement. J Biol Chem 1999; 274: 17968-74.
130. Heit B, Tavener S, Raharjo E, Kubes P. An intracellular signaling hierarchy determines direction of migration in opposing chemotactic gradients. J Cell Biol 2002; 159: 91-102.
131. Burdon PC, Martin C, Rankin SM. Migration across the sinusoidal endothelium regulates neutrophil mobilization in response to ELR + CXC chemokines. Br J Haematol 2008; 142: 100-8.
132. Ishizuka T, Okajima F, Ishiwara M, et al. Sensitized mast cells migrate toward the antigen: a response regulated by p38 mitogen- activated protein kinase and Rho-associated coiled-coil-forming protein kinase. J Immunol 2001; 167: 2298-304.
133. Rousseau S, Dolado I, Beardmore V, et al. CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP- K2-HSP27 pathway. Cell Signal 2006; 18: 1897-905.
134. Badr G, Borhis G, Lefevre EA, et al. BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood 2008; 111: 2744-54.
135. Juarez JG, Thien M, Dela Pena A, Baraz R, Bradstock KF, Bendall LJ. CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK. Br J Haematol 2009; 145: 491-9.
136. Miron T, Vancompernolle K, Vandekerckhove J, Wilchek M, Geiger B. A 25-kD inhibitor of actin polymerization is a low molecular mass heat shock protein. J Cell Biol 1991; 114: 255-61.
137. Eyers CE, McNeill H, Knebel A, et al. The phosphorylation of CapZ-interacting protein (CapZIP) by stress-activated protein kinases triggers its dissociation from CapZ. Biochem J 2005; 389: 127-35.
138. Kobayashi M, Nishita M, Mishima T, Ohashi K, Mizuno K. MAPKAPK-2-mediated LIM-kinase activation is critical for VEGF-induced actin remodeling and cell migration. EMBO J 2006; 25: 713-26.
139. Huang C, Borchers CH, Schaller MD, Jacobson K. Phosphorylation of paxillin by p38MAPK is involved in the neurite extension of PC-12 cells. J Cell Biol 2004; 164: 593-602.
140. Ko J, Yun CY, Lee JS, Kim JH, Kim IS. p38 MAPK and ERK activation by 9-cis-retinoic acid induces chemokine receptors CCR1 and CCR2 expression in human monocytic THP-1 cells. Exp Mol Med 2007; 39: 129-38.
141. Woo CH, Lim JH, Kim JH. Lipopolysaccharide induces matrix metalloproteinase-9 expression via a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 pathway in Raw 264.7 cells. J Immunol 2004; 173: 6973-80.
142. Nguyen J, Gogusev J, Knapnougel P, Bauvois B. Protein tyrosine kinase and p38 MAP kinase pathways are involved in stimulation of matrix metalloproteinase-9 by TNF-alpha in human monocytes. Immunol Lett 2006; 106: 34-41.
143. Hecht M, Heider U, Kaiser M, von Metzler I, Sterz J, Sezer O. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol 2007; 138: 446-58.
144. Scaldaferri F, Sans M, Vetrano S, et al. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur J Immunol 2009; 39: 290-300.
145. Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-14.
146. Medicherla S, Reddy M, Ying J, et al. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res 2008; 28: 3827-33.
147. Vanderkerken K, Medicherla S, Coulton L, et al. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res 2007; 67: 4572-7.
148. Ishitsuka K, Hideshima T, Neri P, et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol 2008; 141: 598-606.
149. Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 2005; 12: 2979-94.
150. Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 2005; 8: 421-30.
151. Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol 2010; 50: 94-100.
152. Genovese M, Cohen S, Wofsy D, et al. A randomized, double- blind, placebo-controlled phase 2 study of an oral p38 MAPK inhibitor, SCIO-469, in patients with active rheumatoid arthritis. 72nd American College of Rheumatology Annual Scientific Meeting; 24-29 October 2008; San Francisco 2008. p. S431-2.
153. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009; 60: 335-44.
154. Alten RE, Zerbini C, Jeka S, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis 2010; 69: 364-7.
155. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009; 60: 1232-41.
156. Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen- activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 325-34.
157. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress- activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterol 2002; 122: 7-14.
158. Juarez J, Baraz R, Gaundar S, Bradstock K, Bendall L. Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia. Haematologica 2007; 92: 450-9.
159. Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 2003; 23: 8306-15.
160. Sanchez Y, Amran D, Fernandez C, de Blas E, Aller P. Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK, AMPK). Int J Cancer 2008; 123: 1205-14.
161. Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M, Ruvolo PP. The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 2005; 19: 1350-4.
162. Wang N, Wang LW, Gou BD, Zhang TL, Wang K. Realgar- induced differentiation is associated with MAPK pathways in HL- 60 cells. Cell Biol Int 2008; 32: 1497-505.
163. Seo SK, Lee HC, Woo SH, et al. Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunc- tion. Apoptosis 2007; 12: 195-209.
164. Shimizu T, Nakazato T, Xian MJ, Sagawa M, Ikeda Y, Kizaki M. Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. Biochem Pharmacol 2006; 71: 742-50.